Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The Learning Portal will be under maintenance Monday, 6 December between 6 AM and 5 PM EST. Portal functionality will be unavailable during this window.
We apologize for any inconvenience caused during this time.
Posted 12 July 2012 | By Alexander Gaffney, RAC, Louise Zornoza,
Brazilian regulatory authorities are looking to keep newly-won authority to deny the grant of patents for medical products-authority won in 2012 as the result of patent reforms.
Speaking at a 10 July 2012 hearing before the Brazilian House of Representatives, Anvisa's Coordinator for Intellectual Property, Antonio Carlos Bezerra, told legislators that the agency ensures that there is no "undue delay in the arrival of competitors."
"An estimated $28 billion economy for the population under the introduction of generics into the market," added Bezerra.
The House is currently considering Bill 3.709/2008, which would remove Anvisa's veto authority by ending their participation in the evaluation of patents entirely.
The issue of access to drugs is particularly prescient in Brazil, where citizens are guaranteed the ability to have universal access to medicines by their constitution. A statement by Anvisa said taking away their pre-review authority would "[carry] risks for the public health model of the country."
Anivsa - Debate on prior informed consent brings together experts in the House
Regulatory Focus - Brazil: Regulatory Agency Gets Authority to Deny Patents
Get more Breaking News from RegLink
Tags: Veto, Legislation, House, Generics, Patent, pharmaceutical, brazil, drug
Regulatory Focus newsletters
All the biggest regulatory news and happenings.